|
|
|
|
Pramipexole is a new,selective,nonergoline agonist that acts on D2 and preferentially on D3 dopamine receptors.The results of the study showed that the UPDRS part II improved by 26.7%for pramipexole(p=0.0002)and 14%of bromocriptine(p=0.02)versus 4.8%for placebo.The UPDRS part III showed improvement in 34%for pramipexole(p=0.0006)and 23.8%for bromocriptine(p=0. 01)versus 5.7%for placebo.There were no major differences in safety data. In the active treatment groups there were more reports of dyskinesia and nausea compared with placebo.In regard to comparison of the Global Clinical Assessment of Efficacy between active treatment groups,there was a trend to significance(p=0.056)in favor of pramipexole.We conclude that pramipexole-treated patients with advanced PD improved significantly more than placebo for both primary end points. |
|